BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars - 2Florence's Uffizi Gallery moves treasures to safety after cyberattack
- 3Nature: 10 High priority Setting up camp Spots In Europe
- 4Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- 5There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- The most effective method to Oversee Unsold SUVs in the Car Business
- Foot fossil discovery could reshape human evolutionary history
- Humpback whale stranded on Germany's Baltic coast frees itself
- ICAS calls for clearer safeguards in FRC’s TCA policy
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Scientists solve the mystery of the prehistoric 'Burtele Foot'
